PTC Therapeutics, Inc. (PTCT)
NEUTRALFundamental
58
Kurs
$72.08
Marktkapitalisierung
$5.77B
Teil 1 · Was das Unternehmen wert ist
Übersicht
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$1.01B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-38M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$702M
Gesamtes Eigenkapital
$-205M
Gesamtverbindlichkeiten
$3.10B
Current Ratio
3.39
Zinsdeckungsgrad
-
Schulden/EBITDA
0.77
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$150.93
Aktueller Kurs
$72.08
Sicherheitsmarge
+52.2%
Innerer-Wert-Spanne
$98.10 - $203.75
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
8.89
ROE
-332.5%
P/B-Verhältnis
-
P/FCF
8.22
Bruttomarge
-
ROIC
4.0%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
4.0%
WACC
7.2%
ROIC − WACC
-3.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (10)
- EPS shows upward trend
- Price CAGR 20.40%
- P/FCF 8.22
- Operating Margin 12.5%
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Revenue Growth 5Y 135.4%
- Analyst Consensus 81% Buy
- Piotroski F-Score 6/9
Nicht bestanden (9)
- EPS CAGR 3.91%
- ROIC 4.0%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -351.9%
- Earnings Surprise avg -1034.0%
- Share Dilution 14.2%
- Net Margin Trend -3.8% vs 35.6%
Nicht verfügbar (9)
- Gross Margin NaN%
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 53 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director | 79 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 40 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 58 |
| Mr. Eric Pauwels | Chief Business Officer | 63 |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 57 |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services | 46 |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer | - |
| Ms. Ellen Cavaleri | Head of Investor Relations | - |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer | 64 |
Prüfungsrisiko
3
Vorstandsrisiko
3
Vergütungsrisiko
4
Aktionärsrechterisiko
7
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for PTCT, sourced from Markets Gazette.
- 3/3/2026POSITIVEInvestment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Investor confidence in PTC Therapeutics (PTCT) appears to be on the rise, following a recent SEC filing that disclosed a significant purchase of 41,000 shares by an investment manager. This strategic move suggests a positive outlook on the future of the company, which specializes in developing therapies for rare diseases. The increased stake by an institutional player can be interpreted as a bullish signal, indicating that the market might be underestimating the potential of PTC Therapeutics' portfolio of commercial products and investigational candidates. Investors should closely monitor the stock's performance, as such an endorsement often precedes positive price movements, reflecting stronger conviction in the company's business model and long-term growth prospects within the biopharmaceutical sector.
via Markets Gazette